Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia
NCT05928390Phase 2Active, not recruiting
- Sponsor
- Recordati SpA
- Start
- Jan 2024
- Primary completion
- Oct 2026
- Modality
- Peptides, Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of pasireotide LAR in post-bariatric hypoglycemia (PBH), sponsored by Recordati SpA. Started Jan 2024; status: active, not recruiting.
02
Drugs
pasireotide LAR
03
Conditions
post-bariatric hypoglycemia (PBH)
Beyond the preview
Go deeper on NCT05928390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05928390.